hENT1 as a Predictive Biomarker in PDAC—Letter-Reference-Cited by-同舟云学术

hENT1 as a Predictive Biomarker in PDAC—Letter

Published:2023-08-01 Issue:15 Volume:29 Page:2944-2944
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Boyd Lenka N.C.¹²³^ORCID,Ali Mahsoem¹²³^ORCID,Puik Jisce R.¹²³^ORCID,Meijer Laura L.⁴^ORCID,Le Large Tessa Y.S.¹²³^ORCID,van Laarhoven Hanneke W.M.³⁵^ORCID,Giovannetti Elisa²³⁶^ORCID,Kazemier Geert¹³^ORCID

Affiliation:

1. 1Amsterdam UMC, location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands.

2. 2Amsterdam UMC, location Vrije Universiteit, Department of Medical Oncology, Amsterdam, the Netherlands.

3. 3Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.

4. 4Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, the Netherlands.

5. 5Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, the Netherlands.

6. 6Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy.

Funder

KWF Kankerbestrijding

Bennonk Foundation

Fondazione AIRC per la ricerca sul cancro ETS

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/29/15/2944/3350823/2944.pdf

Reference4 articles.

1. hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma (PDAC);Perera;Clin Cancer Res,2022

2. hENT1 testing in pancreatic ductal adenocarcinoma: are we ready? A multimodal evaluation of hENT1 status;Raffenne;Cancers,2019

3. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets;Le Large;JCI Insight,2020

4. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity;Rauchwerger;Cancer Res,2000